Cordarone is one of the more internationally available antiarrhythmic preparations, marketed in 50 countries. Its active ingredient is amiodarone hydrochloride, a medication classified within the antiarrhythmic category of cardiac therapies. This page is intended for international readers — travellers, expatriates, and family members — who need to identify the medication or its local equivalent across borders.
Amiodarone is prescribed in the management of serious cardiac rhythm disturbances, including ventricular tachycardia, ventricular fibrillation, atrial flutter, and arrhythmias associated with Wolff-Parkinson-White syndrome. The structured indication list further down this page details the registered uses recognised across the markets where Cordarone is authorised, and reflects the role of amiodarone as a long-established option within rhythm-control therapy.
Because Cordarone is widely distributed, travellers and expatriates frequently encounter the same medication abroad — sometimes labelled as Cordarone, sometimes as an amiodarone-containing generic. Markets where the brand is registered include France, Canada, China, Egypt, and Colombia, but regulatory packaging, prescription pathways, and even tablet appearance can vary considerably from one country to another. A pharmacist in any of these markets can confirm whether a locally available amiodarone product corresponds to what the patient was previously taking.
Other medications within the broader antiarrhythmic class are also sold in many of the same markets under different molecules and brand names, although they are not freely interchangeable with amiodarone. A local pharmacist can identify regional options, but switching between antiarrhythmic agents is a clinical decision rather than a substitution at the counter. Anyone managing rhythm-control therapy while travelling or relocating should treat any change to their regimen as something to be reviewed with a cardiologist or treating physician.
14/10/2016
Cordarone is prescribed in the management of serious cardiac rhythm disturbances, including ventricular tachycardia, ventricular fibrillation, atrial flutter, and arrhythmias associated with Wolff-Parkinson-White syndrome. It belongs to the antiarrhythmic class of cardiac therapies. The structured indication block further down this page lists the specific registered uses recognised by national regulators across the markets where Cordarone is authorised.
Cordarone contains amiodarone hydrochloride, classified as an antiarrhythmic agent within the broader category of cardiac therapies. Amiodarone is the same molecule whether sold under the Cordarone brand or as a generic — internationally, the active ingredient circulates under multiple commercial names, particularly in markets where multiple manufacturers produce amiodarone-containing products in parallel.
Cordarone is registered in 50 countries spanning Europe, the Americas, Asia, and parts of Africa. Examples include France, Canada, China, Egypt, Colombia, Denmark, and Bangladesh. If your country is not represented in the list shown on this page, a local pharmacist can usually confirm whether amiodarone is available in that market under a different brand name or as a generic preparation.
Amiodarone is marketed under several brand names worldwide, particularly in markets where the original patent has long expired and multiple manufacturers produce amiodarone-containing products. Other medications within the broader antiarrhythmic category also exist, although they are not interchangeable without medical guidance — molecules within this class differ meaningfully in profile. To identify a local amiodarone product, search the active ingredient on Pill2Trip or ask a pharmacist.
Yes. Cordarone is a prescription medication, and antiarrhythmic therapy in particular is calibrated to a patient's full cardiac history, concurrent medications, and individual circumstances. This matters especially for travellers and people relocating between countries, since prescription requirements, branded packaging, and available generics differ across regulatory regimes. Any decision to start, stop, switch, or substitute amiodarone should sit with a healthcare provider familiar with the patient.
